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Abstract: Candida auris has emerged globally as a multidrug-resistant fungal pathogen. Isolates of
C. auris are reported to be misidentified as Candida haemulonii. The aim of the study was to compare
the heat production profiles of C. auris strains and other Candida spp. and evaluate their antifungal
susceptibility using isothermal microcalorimetry. The minimum heat inhibitory concentrations
(MHIC) and the minimum biofilm fungicidal concentration (MBFC) were defined as the lowest
antimicrobial concentration leading to the lack of heat flow production after 24 h for planktonic
cells and 48 h for biofilm-embedded cells. C. auris exhibited a peculiar heat production profile.
Thermogenic parameters of C. auris suggested a slower growth rate compared to Candida lusitaniae and
a different distinct heat profile compared to that of C. haemulonii species complex strains, although they
all belong to the Metschnikowiaceae clade. Amphotericin B MHIC and MBFC were 0.5 µg/mL and
≥8 µg/mL, respectively. C. auris strains were non-susceptible to fluconazole at tested concentrations
(MHIC > 128 µg/mL, MBFC > 256 µg/mL). The heat curve represents a fingerprint of C. auris,
which distinguished it from other species. Treatment based on amphotericin B represents a potential
therapeutic option for C. auris infection.
Keywords: Candida auris; biofilm; antifungal resistance; isothermal microcalorimetry;
Metschnikowiaceae clade
1. Introduction
Since its initial description in 2009, Candida auris has emerged as a new nosocomial pathogen,
characterized by traits of drug resistance, that may cause fungemia and other deep-seated infections
in at-risk populations, posing a global threat for public health [1,2]. Genetic analyses have
placed C. auris within the Metschnikowiaceae family, most closely related to species of the
Candida haemulonii complex and Candida lusitaniae, with a marked divergence from other Candida
species. Unlike most other Candida spp., C. auris is associated with skin rather than with gastrointestinal
tract colonization and presents an intrinsic resistance to conventional front-line antifungal agents,
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antiseptics, and disinfectants [1]. In fact, resistance to azole is rather common among circulating strains
of C. auris, at least in South Asia, and clones resistant to amphotericin B and echinocandins have also
been described [1,3,4]. C. auris is able to survive and persist in different environments and conditions
with a high grade of resilience and adaptivity [5]. Such a persistent colonizing phenotype of C. auris
may also be linked to its ability to form a biofilm [6–8]. Analogously to other Candida spp., C. auris has
been shown to attach on abiotic surfaces and form biofilms in vitro [8]. In vitro biofilms of C. auris
appeared less thick than those of Candida albicans, mostly due to the lack of hyphae production [9].
Recently, the involvement of C. auris in an intra-articular infection (usually due to biofilm formation)
of a woman with a long-term ankle spacer has also been reported [10].
Due to the ability of C. auris to spread among patients, colonize the hospital environment rapidly,
and easily develop resistance to antifungals, an accurate and timely identification of species paired
to an appropriate determination of C. auris antifungal susceptibilities is the key to control outbreaks
and antifungal therapy [11]. Although C. auris was discovered 10 years ago [12], it is thought to have
been misidentified as C. haemulonii on several occasions by commercial identification systems [13],
suggesting that C. auris has likely been circulating as a human pathogen before 2009. Indeed, the failure
in the misidentification of C. auris is mainly due to systems based on biochemical methods (such as
VITEK 2, Phoenix, and API20C AUX). Matrix-assisted laser desorption ionization–time of flight mass
spectrometry (MALDI-TOF MS) is a specialized proteomic-based technique, which represents a rapid,
accurate, and convenient technology for the identification of microorganisms at the species level.
MALDI-TOF MS based on the comparison of the generated spectra for each sample with the reference
database can differentiate C. auris from other Candida species if the database is fully updated with the
information of that species [10]; otherwise no identification or misidentification will be obtained as
shown recently with external quality assessment [13–15].
Isothermal microcalorimetry (IMC) is a nonspecific analytical tool for the measurement of
heat produced or consumed by chemical reactions or physical changes of state in a specimen
ampoule, including heat generated by complex biological processes in cultured microbial cells [16].
If microorganisms replicate in a microcalorimetry ampoule and produce enough metabolic heat to
exceed the instrument’s detection limit, their exponential growth phase can be detected and observed
in real time. Each microorganism produces a peculiar thermogenic profile which represents a sort of
fingerprinting of the species or strains [17]. Moreover, IMC has been widely employed to evaluate the
metabolic heat produced by both bacteria and fungi and to test their ability to form biofilms on different
materials [18,19]. IMC analysis also proved helpful to evaluate the activity of different antimicrobials,
including antibiotics [20–22], bacteriophages [23,24], and antifungals [25] against planktonic and sessile
microbial cells. To the best of our knowledge, the thermogenic characteristics and the antifungal
susceptibilities of planktonic and biofilm C. auris have not been investigated by microcalorimetry, yet.
Therefore, the aim of the study was to analyze the metabolic heat profiles produced by different
clinical strains of C. auris in comparison to other Candida spp., including those belonging to the same
Metschnikowiaceae family, and evaluate their susceptibility to amphotericin B and to fluconazole in
planktonic and biofilm forms by IMC.
2. Materials and Methods
2.1. Candida Strains and Growth Conditions
C. albicans ATCC 90028, Candida glabrata DSY 562, Candida parapsilosis ATCC 22019 and clinical
strains of C. haemulonii (H 433), Candida duobushaemulonii (D-437), C. lusitaniae (L-719), Candida
pseudohaemulonii (P-430), Candida kefyr (K-629), Candida tropicalis (T 317), and C. auris (reference strain
CBS14916 and clinical strains 10051257, 10051259, 10051266, 10051297) were use in this study (Table 1).
Based on whole-genome sequencing, five different clades of C. auris have been described by region
(East Asian, South Asian, African, South American, and Iranian) [26]. Yeasts were stored using a
cryovial bead preservation system (Microbank; Pro-Lab Diagnostics, Richmond Hill, ON, Canada)
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at −80 ◦C. To find out the best growth conditions, all strains were incubated on Sabouraud dextrose
agar (Oxoid) at 25, 30, and 37 ◦C for 24, 48, and 72 h. After each incubation time point, the colony
size was manually measured by a ruler and a picture was taken. For all antifungal tests, five C. auris
strains were grown on Sabouraud dextrose agar at 37 ◦C for 48 h and the used liquid medium was
RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA). The standard inoculum for all tests was
≈5 × 105 CFU/mL.
Table 1. Candida clinical strains used in this study.
Strains 1FLC 2VRC 3AMB 4CAS 55FC 6MFG 7ITC 8POS 9AFG 10ISA
C. lusitaniae (L-719) ≤0.5 ≤0.12 0.5 0.25 2 0.25 0.012 0.004 0.16 0.004
C. kefyr (K-629) 1 ≤0.12 1 ≤0.12 4 0.12 0.023 0.023 0.12 0.004
C. tropicalis (T 317) 1 ≤0.12 0.5S ≤0.12 ≤1 ≤0.06 0.012 0.008 0.008 0.006
C. haemulonii (H 433) 2 ≤0.12 ≥16 0.25 ≤1 0.25 n.a. n.a. 0.5 n.a.
C. duobushaemulonii (D-437) 2 ≤0.12 2 ≤0.12 ≤1 ≤0.06 n.a. n.a. 0.032 n.a.
C. pseudohaemulonii (P-430) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
C. auris 10051257(467/P/14) 32 2 1.5 ≥8 ≤1 ≥8 1 0.25 ≥8 0.5
C. auris 10051259(471/P/14) 32 1 1 0.25 ≤1 0.125 2 038 0.064 1
C. auris 10051266(1113/P/13) 32 1 1 ≥8 ≤1 ≥8 1 0.25 32 0.5
C. auris 10051297(550/P/14) 32 2 8 ≥8 ≥64 ≥8 2 0.125 8 0.25
C. auris CBS14916 32 0.25 8 0.25 ≥64 0.12 0.064 0.032 0.125 0.032
1 Fluconazole (FLC); 2 voriconazole (VRC); 3 amphotericin B (AMB); 4 caspofungin (CAS); 5 flucytosine (5FC);
6 micafungin (MFG); 7 itraconazole (ITC); 8 posaconazole (POS); 9 anidulafungin (AFG); 10 isavuconazole (ISA).
All C. auris originated from A. Chowdhary, Vallabhbhai Patel Chest Institute (VPCI), Delhi, India. Based on
whole-genome sequencing, five different clades of C. auris have been described by region (East Asian, South Asian,
African, South American, and Iranian) [26].
2.2. Antimicrobial Agents
The powders of sodium-deoxycholate amphotericin B (Sigma-Aldrich Chemie, Taufkirchen,
Germany) and fluconazole (Pfizer, Freiburg, Germany) were used in this study. Amphotericin B and
fluconazole were dissolved in a 2 g/L stock solution with distilled water and stored at −20 ◦C until use.
2.3. Biofilm Formation on Porous Glass Beads
The biofilm forming ability of C. auris was evaluated according to a protocol previously described
for other Candida species, including C. albicans [27]. Briefly, C. auris CBS14916 was propagated as
a biofilm on porous glass beads with a diameter of 2–4 mm, porosity of 0.2 m2/g, and pore size of
60 µm (VitraPor; ROBU, Hattert, Germany) by inoculating two to three colonies of the yeast either in
Sabouraud dextrose broth or RPMI 1640 medium (one bead per 1 mL medium) and incubating beads
at 37 ◦C for 24, 48, or 72 h, respectively. After each time point, beads were washed three times with
0.9% saline solution to remove all planktonic cells and sonicated to dislodge biofilm-embedded yeasts,
as previously described [25,28]. Then, sonication fluids were plated onto Sabouraud dextrose agar
which were incubated for 48 h at 37 ◦C for colony counting [25]. C. albicans biofilms were prepared
with the same conditions and were used as control.
2.4. Characterization and Antifungal Assay by Isothermal Microcalorimetry (IMC)
The metabolically related heat produced by the different Candida species was measured using an
isothermal 48-channel batch calorimeter (TAM III; TA Instruments, Newcastle, DE, USA), as described
previously [27]. Yeast cells of each species (5 × 105 CFU/mL final inoculum) were inoculated in
Sabouraud dextrose broth and incubated in sterile ampoules, which were then placed in the calorimeter.
The heat produced was monitored at 37 ◦C for 48 h.
To determine antifungal activity against planktonic C. auris, yeast cells (5 × 105 CFU/mL final
inoculum) were inoculated in microcalorimetry ampoules filled with RPMI 1640 and twofold serial
dilutions of amphotericin B (0.125–2 µg/mL) and fluconazole (16–128 µg/mL). Heat production was
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measured at 37 ◦C for 48 h. The minimum heat inhibiting concentration (MHIC) for planktonic
yeasts was defined as the lowest antifungal concentration that inhibited the yeast growth-related heat
production during 24–48 h incubation in the microcalorimeter.
To determine cidal activity of the antifungal agents against planktonic yeasts, C. auris suspensions
treated with drugs were plated onto Sabouraud dextrose agar and incubated for 48 h at 37 ◦C,
after microcalorimetry measurements. The minimum fungicidal concentration (MFC) was defined as
the lowest antimicrobial concentration that showed a reduction ≥3 log10 in CFU/mL, as compared to
the CFU/mL number of the initial inoculum.
For the determination of antifungal activity against C. auris biofilm, biofilm beads, obtained
as previously described, were exposed to twofold dilutions of either amphotericin B (1–16 µg/mL)
or fluconazole (128 and 256 µg/mL) in RPMI 1640 medium and incubated again for 24 h at 37 ◦C.
After treatment, the glass beads were rinsed three times with 0.9% saline and transferred into
microcalorimetry ampoules with 3 mL fresh RPMI 1640 medium to measure the re-growth of surviving
cells of biofilms still attached to the bead. Beads without yeasts were used as sterility control. The heat
production was measured at 37 ◦C for 48 h. The minimum biofilm fungicidal concentration (MBFC)
was defined as the lowest antifungal concentration that strongly reduced the number of viable yeast
cells within the biofilm, therefore leading to undetectable heat flow values. The minimum biofilm
eradicating concentration (MBEC) was defined as the lowest antifungal concentration that eradicates
all sessile biofilm cells (0 CFU/bead on plate counts), evaluated by CFU counting after sonication of
beads, as previously described [16,28]. All experiments were performed in triplicate.
2.5. Data Analysis
The resulting data were expressed as heat flow (µW) versus time (h) and as heat (J) versus
time (h). Figures were plotted using GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA).
IMC time to detection (TTD, h) was defined as the time between the insertion of the ampoule into
the microcalorimeter and the exponentially increasing heat flow production exceeding the threshold
of 10 µW [27].The maximum heat flow peak (Pmax, µW), the time of the maximum heat flow peak
(Tmax, h), and the total heat produced (Htot, J) were defined as the highest value of the heat flow–time
curve, the time at which the Pmax was detected, and the cumulative amount of heat produced during
the whole experiment, respectively.
IMC data were converted into microbiologically relevant information such as growth rate (µ, J/h)
and lag phase (λ, h) by deriving according to growth models, as previously reported [17,22,29,30].
3. Results
3.1. Microcalorimetric Analysis of Candida spp.
The metabolic heat produced by planktonic Candida strains during their growth was monitored in
real time for 48 h at 37 ◦C by isothermal microcalorimetry. Figure 1 shows representative thermogenic
profiles of heat flow (Figure 1a) and total heat, (Figure 1b) obtained by different Candida species
including C. auris and other strains in the Metschnikowiaceae clade. In Table 2, values of different
thermogenic parameters (related to curves of Figure 1) are reported. C. parapsilosis ATCC 22019,
C. glabrata DSY 562, and C. kefyr (K-629) showed a similar profile of the heat production curve, although
they exhibited a different Pmax (195.34, 168.44, and 145.10 µW, respectively). All the three species
also were characterized by a similar Tmax, ranging from 6.5 to 7 h. C. lusitaniae (L-719), one of the
Metschnikowiaceae clade, displayed a comparable curve to C. albicans (ATCC 90028) with a similar
Pmax, but with an early Tmax (∆Tmax = 4.19 h). In comparison to the above-mentioned Candida species,
C. auris (CBS14916) and C. tropicalis (T-317) showed a lower Pmax and a delayed Tmax. However, in most
Candida species, the total heat produced was ranging between 4.71 and 5.60 J, except in C. tropicalis,
where the total heat during 48 h was 8.49 J. Among C. auris clinical strains, all four isolates showed
similar heat flow and total heat curves as shown in Figure 2. A different behavior in the heat
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production has been observed in samples containing C. duobushaemulonii (D-437), C. haemulonii (H-433),
and C. pseudohaemulonii (P-430) at tested experimental conditions. All showed a Pmax lower than all
other Candida species analyzed (23.86–29.48 µW) at the last measured time point (46 h); thus, their total
heat values were also lower. Even the lag phase for these three Candida species was similar, ranging
between 17 and 22 h which was in contrast with the lag phase values of other strains ranging between
3.96 and 5.69 h. For most of the strains, the time to detection (TTD) of the heat produced was ranging
from 1.01 to 2.5 h. Only the TTD of C. haemulonii was delayed (7.21 h). C. auris, C. pseudohaemulonii,
and the strains of the C. haemulonii complex exhibited a slower growth rate (0.23–0.14 J/h) at 37 ◦C in
comparison to all the other Candida species (1.04–0.38 J/h).
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Figure 1. Microcalorimetry analysis of Candida spp. Heat flow (a) and total heat (b) curves generated 
by planktonic C. parapsilosis, C. glabrata, C. kefyr, C. lusitaniae, C. albicans, C. tropicalis, C. auris, C. 
duobushaemulonii, C. haemulonii, and C. pseudohaemulonii in RPMI 1640 at 37 °C. 
 
Figure 2. Microcalorimetry analysis of C. auris. Heat flow (a) and total heat (b) curves generated by 
planktonic C. auris 10051257, C. auris 10051259, C. auris 10051266, and C. auris 10051297 in RPMI 1640 
at 37 °C. 
















































l t ic . parapsilosis, C. glabrata, C. kefyr, C. lusitaniae, C. albicans, C. tropicalis, C. auris,
C. duobushaemulonii, C. haemulonii, and C. pseudohaemulonii in RPMI 1640 at 37 ◦C.
Table 2. Microcalorimetric parameters of planktonic Candida species.
Strains Pmax (µW) 1 Tmax (h) 2 Htot (J) 3 TTD (h) 4 λ (h) 5 (µ, J/h) 6
C. parapsilosis ATCC 22019 195.3 6.89 4.86 1.79 5.06 1.04
C. glabrata DSY 562 168.4 6.54 4.71 1.05 3.96 0.60
C. kefyr (K-629) 145.1 6.54 5.60 1.01 4.00 0.52
C. lusitaniae (L 719) 112.3 9.31 4.90 1.01 5.14 0.40
C. albicans ATCC 90028 108.1 10.91 5.02 1.01 5.69 0.38
C. auris CBS14916 65.1 17.07 5.27 1.01 5.19 0.23
C. tropicalis (T 317) 80.3 13.98 8.49 1.01 5.51 0.28
C. duobushaemulonii (D-437) 29.5 46.00 3.46 1.69 21.99 0.18
C. haemulonii (H 433) 23.9 46.00 3.15 7.21 17.64 0.16
C. pseudohaemulonii (P-430) 25.4 46.00 2.91 2.50 20.94 0.14
1 Pmax (µW): the maximum heat flow peak; 2 Tmax (h): time of the maximum heat flow peak; 3 Htot (J): total heat
produced in J; 4 TTD (h): time to detection in h; 5 λ (h): lag phase; 6 µ (J/h): growth rate.
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Figure 2. Microcalorimetry analysis of C. auris. Heat flow (a) and total heat (b) curves generated by
planktonic . auris 10051257, . auris 10051259, . auris 10051266, and C. auris 10051297 in RPMI 1640 at
37 ◦C.
3.2. Analysis of Candida spp. Growth on Solid Medium
The ability of C. auris, C. duobushaemulonii, C. haemulonii, and C. pseudohaemulonii to grow on agar
medium at 37 ◦C was also impaired as suggest by the small size of C. auris colonies (CBS14916), manually
measured, and the absence of any colonies of C. pseudohaemulonii, C. haemulonii, and C. duobushaemulonii
after 24 h of plate incubation (Figure 3 and Table 3).
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Table 3. Average of colony size of Candida species grown at different temperatures.
Strains
25 ◦C 30 ◦C 37 ◦C
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
C. parapsilosis ATCC 22019 n.g 1. 1 2 0.5 1–2 3 1 2 3
C. glabrata DSY 562 n.g. 1 2 0.5 2 3 1 2 3
C. kefyr (K-629) n.g. 1 2 0.5 1 1–2 1 2–3 3
C. lusitaniae (L-719) n.g. 0.5 1 0.5 1 1 0.5 1–2 2
C. albicans ATCC 90028 n.g. 0.5 1 0.5 1–2 2 0.5 1–2 2
C. auris CBS14916 n.g. <0.5 1 <0.5 1 1 0.5 1–2 3
C. tropicalis (T 317) n.g. 1 2 0.5 1 1 1 1–2 2
C. duobushaemulonii (D-437) n.g. <0.5 1 n.g. n.g. n.g. n.g. 0.5 1
C. haemulonii (H 433) n.g. 0.5 1 0.5 0.5 1 n.g. <0.5 0.5
C. pseudohaemulonii (P-430) n.g. 0.5 1 <0.5 0.5 0.5 n.g <0.5 1
1 n.g.: no growth. Numbers referring to colony size in mm.
3.3. Analysis of C. auris Biofilm Formation
The ability of C. auris (CBS14916) to form biofilm was evaluated as CFU number of yeast cells
detached by washed porous glass beads (to remove planktonic cells) after 24, 48, and 72 h incubation
of Candida cells either in Sabouraud or in RPMI 1640 dextrose broth at 37 ◦C (Figure 4). C. albicans
ATCC 90028 was used as a control of biofilm formation on the same material. After 24 h incubation,
the number of C. auris CFU ranged between 105 and 106 CFU/mL in both media which was comparable
to the number of C. albicans yeasts detached, suggesting that no difference in biofilm cell growth
occurred in Sabouraud and RPMI 1640. The number of Candida cells removed from beads remained
similar even in the case of a prolonged time of biofilm formation. This has been observed for both
investigated Candida species.
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with MFC ranging between 0.5 and 1 µg/mL. While, MBFC values for amphotericin B were higher 
than MHIC, resulting in 8 µg/mL for C. auris 10051257 and 10051297 and >8 µg/mL for C. auris 
10051259 and 10051266. MBFC values also corresponded to eradicating concentrations (MBEC). By 
contrast, both planktonic and sessile strains of C. auris were non-susceptible to the tested 
concentrations of fluconazole (128 and 256 µg/mL, respectively). 
Figure 4. Biofilm of C. auris CBS14916 (a) and C. albicans ATCC 90028 (b) formed on porous glass beads.
CFU number of C. auris and C. albicans dislodged from glass beads by sonication after incubation in
either Sabouraud or RPMI 1640 broth at 37 ◦C for 24, 48, and 72 h.
3.4. Susceptibility Assay of Planktonic and Biofilm-embedded C. auris to Amphotericin B and Fluconazole
by IMC
Antifungal activity of amphotericin B and fluconazole was assayed against planktonic (Figure 5)
and biofilm (Figure 6) yeasts of C. auris by IMC. Values of MHIC, MFC, BFC, and MBEC are reported
in Table 4. All planktonic strains of C. auris were susc ptible o 0.5 µg/mL amphotericin B with
MFC ranging between 0.5 and 1 µg/mL. While, MBFC values for amphotericin B were higher than
MHIC, resulting in 8 µg/mL for C. auris 10051257 and 10051297 and >8 µg/mL for C. auris 10051259
and 10051266. MBFC values also corresponded to eradicating concentrations (MBEC). By contrast,
both planktonic and sessile strains of C. auris were non-susceptible to the tested concentrations of
fluconazole (128 and 256 µg/mL, respectively).
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different concentrations of amphotericin B (a,c,e,g) and fluconazole (b,d,f,h). Numbers indicate the 
antifungal concentrations (µg/mL). GC: growth control (without antifungal agent). MHIC is defined 
as the lowest antifungal concentration that inhibited the yeast growth-related heat production during 
24–48 h incubation in the microcalorimeter. The circled value denotes the minimum fungicidal 
concentration (MFC). 
Figure 5. Heat flow curves generated by planktonic strains of C. auris CBS14916 (a,b), C. auris 10051257
(c,d), C. auris 10051259 (e,f), C. auris 10051266 (g,h), and C. auris 10051297 (i,j) in the presence of
different concentrations of amphotericin B (a,c,e,g) and fluconazole (b,d,f,h). Numbers indicate the
antifungal concentrations (µg/mL). GC: growth control (without antifungal agent). MHIC is defined as
the lowest antifungal concentration that inhibited the yeast growth-related heat production during
24–48 h incubation in the microcalorimeter. The circled value denotes the minimum fungicidal
concentration (MFC).
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Figure 6. Heat flow curves generated by biofilm-embedded yeasts of C. auris 10051257 (a,b), C. auris
10051259 (c,d), C. auris 10051266 (e,f), and C. auris 10051297 (g,h) after treatment with different
concentrations of amphotericin B (a,c,e,g) and fluconazole (b,d,f,h). Numbers indicate the antifungal
concentrations (µg/mL). GC: growth control (without any antifungal treatment). The minimum
biofilm fungicidal concentration (MBFC) was defined as the lowest antifungal concentration which
led to undetectable heat flow values. The circled value denotes the minimum biofilm eradicating
concentration (MBEC).
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Table 4. Values of MHIC, MBFC, MFC, and MBEC (µg/mL) of amphotericin B and fluconazole against
planktonic and biofilm C. auris strains.
Strains
IMC 1 Plating
Planktonic Biofilm Planktonic Biofilm
MHIC 2 MBFC 3 MFC 4 MBEC 5
AMB 6 FLC7 AMB FLC AMB FLC AMB FLC
C. auris 10051257 0.5 >128 8 >256 1 >128 8 >256
C. auris 10051259 0.5 >128 >8 >256 1 >128 >8 >256
C. auris 10051266 0.5 >128 >8 >256 1 >128 >8 >256
C. auris 10051297 0.5 >128 8 >256 1 >128 8 >256
C. auris CBS14916 0.5 >128 n.a.8 >256 0.5 >128 n.a. >256
1 IMC: isothermal microcalorimetry; 2 MHIC: minimum heat inhibition concentration; 3 MBFC: minimum biofilm
fungicidal concentration; 4 MFC: minimum fungicidal concentration; 5 MBEC: minimal biofilm eradication
concentration; 6 AMB: amphotericin B; 7 FLC: fluconazole; 8 n.a.: not assayed. Concentration values are expressed
as µg/mL.
4. Discussion
Among different Candida spp., C. albicans is the main etiological agent of candidiasis [31].
However, non-albicans Candida species have recently gained scientific and epidemiological interest
as their frequency of detection is increasing worldwide. This shift to non-albicans Candida species
has also increased with the increasing number of diagnosis of infection due to C. auris. C. auris is
a newly emerging multidrug-resistant fungal pathogen, associated with severe invasive infection
and outbreaks [5,32–35]. As C. auris is associated to high mortality rates, an accurate and prompt
identification of this species and the susceptibility/resistance evaluation is fundamental to set the
appropriate antifungal therapy [13]. Here, we used IMC to analyze the metabolic heat produced by
C. auris and compare it to that produced by C. albicans and non-albicans Candida species. Our data suggest
that at 37 ◦C in our experimental conditions, C. auris is able to replicate slower (µ = 0.23 J/h; generation
time 180 min) than other Candida species (C. albicans µ = 0.38 J/h; generation time = 108 min), but faster
than C. pseudohaemulonii (µ = 0.14 J/h; generation time = 297 min) and C. haemulonii (µ = 0.16 J/h;
generation time = 259 min). Moreover, the ability of C. auris to grow on solid medium and form visible
colonies at different temperatures and within 24–48 h suggests that this species is more adapted to
high temperature in comparison to other species belonging to the same family. This observation is in
agreement with the analysis of phylogenetic and thermotolerance performed on C. auris, where the
increase in ambient temperatures as a result of global warming may have acclimatized the organism to
adapt to and survive at different host temperatures [36,37]. C. auris showed a peculiar thermogenic
profile, with a lower and larger heat flow curve compared to that observed in other Candida species.
Within the same species, all clinical strains of C. auris showed a similar thermogenic profile. Although
five is a low number, the analysis of additional C. auris isolates might confirm the capability of IMC to
discriminate C. auris by its characteristic metabolic heat curve, which represents a unique fingerprinting
for this species. A limitation of our study is that we only included isolates belonging to the largest
Clade I. Potential phenotypic variation between different clades may show other thermogenic profiles.
As reported by different authors, C. auris is able to form biofilms in vitro and probably in vivo [7–9].
Sherry and colleagues first identified that C. auris was able to produce intermediate quantities of
biomass compared to C. albicans (high producer) and C. glabrata (low producer) [9]. We confirm this
observation by letting C. auris (reference strain) form a biofilm on porous glass beads, a technique widely
used by our group to study bacterial [21,22,38,39] and fungal biofilms, including the susceptibility of
C. albicans to different antifungal agents [25,27], and performing analysis by IMC. To enumerate yeast
cells attached on the beads we used sonication to detach yeast cells from the material and disperse yeast
aggregates [25]. By using C. albicans biofilm as control, we observed that C. auris was able to attach on
porous glass beads and form a sessile community as suggested by the same CFU number recovered
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after sonication of both species. Although we would need microscopy to evaluate the presence of
extracellular matrix and 3D-structure of a biofilm, in analogy to C. albicans, we are confident that
C. auris also established biofilms on the beads. As the increase in time of yeasts/beads incubation
did not change the number of CFUs recovered, we used this incubation for antifungal susceptibility
experiments. As C. auris was recently discovered, no definitive MIC breakpoints exist, but tentative
breakpoints and epidemiological cutoff valueshave been suggested [40,41]. Regarding fluconazole, we
observed a correlation between MIC values obtained by VITEK2 and MHIC values observed by IMC,
in both cases higher than 32 µg/mL the tentative breakpoint for nonsusceptibility. These values are
in agreement with published susceptibility data which suggest that most circulating C. auris strains
are characterized by high fluconazole MICs (>64 µg/mL) and variable susceptibility to amphotericin
B and echinocandins [4,13,41]. By contrast, a discrepancy was seen in MHIC for amphotericin B in
comparison to the MIC for four of five strains. MIC values obtained by VITEK 2 for all strains, except C.
auris 10051259 were 16 times (or more) higher than those of MHIC, thus all these strains of C. auris were
resistant to amphotericin B, based on the commercial system. The evaluation of the antibiofilm activity
of amphotericin B by IMC revealed that all C. auris species were susceptible to higher concentrations
of the polyene (MBFC and MBEC ≥8 µg/mL) compared to the MHIC obtained for planktonic yeast.
This is in agreement with data recently reported in the literature [6]. Despite failure to produce
biofilms as robust as those of C. albicans, sessile C. auris were shown to tolerate higher concentrations
of amphotericin B, although its planktonic counterpart was susceptible to lower concentrations of the
drug [9]. Moreover, Kean et al. suggested that biofilm-embedded cells were phenotypically tolerant to
all classes of antifungals [6]. By transcriptional analysis of C. auris genes, they found that tolerance is
correlated with increase of eﬄux pumps gene expression for both ATP-binding cassette and major
facilitator superfamily (MFS) transporters and the upregulation of genes encoding for molecules
involved in extracellular matrix formation [7]. Although these two phenomena explain resistance to
azoles well, it might be that these phenomena also contribute to polyene tolerance. The mechanisms
employed by C. auris to survive and persist in the environment are unknown, but there is evidence to
suggest that biofilm formation may play a key role, as has been suggested for other microorganisms
well adapted to hostile conditions in biofilms. In conclusion, IMC was useful to distinguish C. auris
from other Candida species, such as C. haemulonii and it might be useful in the future to investigate more
in depth the behavior of C. auris biofilm on different materials. Treatment based on amphotericin B
represents a potential therapeutic option for C. auris infection, which can be easily tested by using IMC.
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